OSTEOARTHRITIS
Nonsignificant differences in outcome at follow-up between low and high-MW HA for knee OA
Clin Exp Rheumatol. 2005 Mar-Apr;23(2):213-892 patients with Kellgren-Lawrence grade III knee osteoarthritis were randomized to three weekly intraarticular injections of either low molecular weight hyaluronic acid (LMW HA; Orthovisc, Anika Therapeutics) or high molecular weight hyaluronic acid (HMW HA; Hylan G-F20, Synvisc, Wyeth). Patients were assessed for improvement from baseline in pain at rest, pain during activity, pain during stair climbing, pain during transfer activities, walking distance, knee range of motion, and Hospital for Special Surgery (HSS) score after 1, 2, 3, and 6 weeks, and 3, 6, and 12 months. Significant differences in improvement in pain were noted in favour of the LMW HA group for pain at rest at 3 months and pain during activity at 6 weeks. Nonetheless, all measures demonstrated non-significant differences between groups at 6 and 12 months.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
